[go: up one dir, main page]

NO20080438L - Proteaser til farmasoytisk anvendelse - Google Patents

Proteaser til farmasoytisk anvendelse

Info

Publication number
NO20080438L
NO20080438L NO20080438A NO20080438A NO20080438L NO 20080438 L NO20080438 L NO 20080438L NO 20080438 A NO20080438 A NO 20080438A NO 20080438 A NO20080438 A NO 20080438A NO 20080438 L NO20080438 L NO 20080438L
Authority
NO
Norway
Prior art keywords
proteases
pharmaceutical use
diabetes
type
pancreatitis
Prior art date
Application number
NO20080438A
Other languages
English (en)
Norwegian (no)
Inventor
Peter-Colin Gregory
Allan Svendsen
Claus Crone Fuglsang
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Publication of NO20080438L publication Critical patent/NO20080438L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20080438A 2005-06-24 2008-01-23 Proteaser til farmasoytisk anvendelse NO20080438L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200500930 2005-06-24
DKPA200501643 2005-11-23
PCT/DK2006/000353 WO2006136160A2 (fr) 2005-06-24 2006-06-16 Proteases a usage pharmaceutique

Publications (1)

Publication Number Publication Date
NO20080438L true NO20080438L (no) 2008-02-15

Family

ID=36808352

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080438A NO20080438L (no) 2005-06-24 2008-01-23 Proteaser til farmasoytisk anvendelse

Country Status (13)

Country Link
US (3) US20080317726A1 (fr)
EP (1) EP1896058A2 (fr)
JP (1) JP2008546395A (fr)
KR (1) KR20080017039A (fr)
AU (1) AU2006261443A1 (fr)
BR (1) BRPI0611936A2 (fr)
CA (1) CA2612806A1 (fr)
IL (1) IL187510A0 (fr)
MX (1) MX2007015474A (fr)
NO (1) NO20080438L (fr)
NZ (1) NZ563777A (fr)
RU (1) RU2420578C2 (fr)
WO (1) WO2006136160A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1896057A2 (fr) * 2005-06-24 2008-03-12 Novozymes A/S Amylases à usage pharmaceutique
EP2455460A3 (fr) 2006-12-21 2012-12-26 Novozymes A/S Variantes de lipase pour utilisation pharmaceutique
GB2465814B (en) * 2008-06-19 2011-10-26 Tarig Sayed Mustafa Arbab Method,composition and device for the treatment of enzymes and saccharides disorders
US20110171294A1 (en) * 2008-09-30 2011-07-14 Dsm Ip Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency
US8262912B1 (en) * 2009-06-05 2012-09-11 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
US9056265B2 (en) 2009-06-05 2015-06-16 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
WO2011000924A1 (fr) 2009-07-03 2011-01-06 Abbott Products Gmbh Amylase séchée par pulvérisation, préparations pharmaceutiques la comprenant et son utilisation
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
WO2014130007A1 (fr) * 2013-02-19 2014-08-28 Deerland Enzymes, Inc. Compositions protéolytiques permettant une dégradation rapide et poussée des compléments protéiques
WO2017080511A1 (fr) * 2015-11-12 2017-05-18 Novozymes A/S Procédés d'agitation, d'aération et/ou de fermentation produisant une mousse réduite
PL3675647T3 (pl) 2017-09-01 2025-02-24 Novozymes A/S Dodatki paszowe dla zwierząt zawierające polipeptyd o aktywności proteazy i ich zastosowania
US20240368643A1 (en) * 2021-06-04 2024-11-07 Amyris, Inc. Methods of purifying cannabinoids
AU2023272468A1 (en) 2022-05-14 2024-11-14 Novonesis Plant Biosolutions A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US6413512B1 (en) * 1998-02-13 2002-07-02 National Enzyme Company Composition and method for treating disease by increasing activated α2 macroglobulin in the blood and extravascular tissue
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
DK1162995T3 (da) * 1999-03-17 2003-06-23 Solvay Pharm Gmbh Enzymer til behandling af diabetes mellitus type I
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
CA2441595C (fr) * 2001-03-23 2012-07-03 Genencor International, Inc. Proteines provoquant une reaction immunogene modifiee, et methodes de production et d'utilisation desdites proteines
RU2201763C1 (ru) * 2001-12-29 2003-04-10 Закрытое акционерное общество "Брынцалов-А" Полиферментное средство ферестал
EP1578935A2 (fr) * 2002-10-10 2005-09-28 Diversa Corporation Proteases, acides nucleiques les codant et leurs procedes de fabrication et d'utilisation
DE10260903A1 (de) * 2002-12-20 2004-07-08 Henkel Kgaa Neue Perhydrolasen
WO2004078773A1 (fr) * 2003-03-03 2004-09-16 Oregon Health And Science University Proteines de stabilisation destinees a etre utilisees dans des produits d'hygiene personnelle, cosmetiques et pharmaceutiques

Also Published As

Publication number Publication date
RU2008102738A (ru) 2009-07-27
WO2006136160A2 (fr) 2006-12-28
AU2006261443A1 (en) 2006-12-28
BRPI0611936A2 (pt) 2011-02-22
JP2008546395A (ja) 2008-12-25
EP1896058A2 (fr) 2008-03-12
KR20080017039A (ko) 2008-02-25
IL187510A0 (en) 2008-03-20
NZ563777A (en) 2010-08-27
MX2007015474A (es) 2008-04-22
US20110110910A1 (en) 2011-05-12
US20100135978A1 (en) 2010-06-03
RU2420578C2 (ru) 2011-06-10
CA2612806A1 (fr) 2006-12-28
WO2006136160A3 (fr) 2007-09-20
US20080317726A1 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
NO20080438L (no) Proteaser til farmasoytisk anvendelse
DK1755656T3 (da) Enzymer til farmaceutisk anvendelse
NO20080439L (no) Amylaser til farmasoytisk anvendelse
NO20080437L (no) Lipaser til farmasoytisk anvendelse
Araujo et al. Peptidase specificity characterization of C-and N-terminal catalytic sites of angiotensin I-converting enzyme
WO2005111203A3 (fr) $g(a)-amylases mutantes
NZ596269A (en) Protease screening methods and proteases identified thereby
NO20033261L (no) Nye blandinger av mikrobielle enzymer
NO20092729L (no) Lipasevarianter for farmasoytisk anvendelse
WO2008021987A3 (fr) Formulations d'enzymes protéolytiques
DK1162995T3 (da) Enzymer til behandling af diabetes mellitus type I
MX2010004371A (es) Proteasa de streptomyces.
MX2009005655A (es) Composiciones y usos de un polipeptido alfa-amilasa del bacilo de la especie 195.
NZ606504A (en) Modified proteases that inhibit complement activation
ES2126743T3 (es) Alfa-amilasa oxidativamente estable.
UA103215C2 (uk) Поліпептид з ксиланазною активністю
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
Schokker et al. Kinetics of Thermal Inactivation of the Extracellular Proteinase from Pseudomonas f luorescens 22F: Influence of pH, Calcium, and Protein
WO2005007663A3 (fr) Substrats d'enzymes fluorogenes et leurs utilisations
Hook Unique neuronal functions of cathepsin L and cathepsin B in secretory vesicles: biosynthesis of peptides in neurotransmission and neurodegenerative disease
RU2013150276A (ru) Способ экспрессии
NZ560648A (en) Formulation for aviptadil (vasoactive intestinal peptide, VIP)
Choi et al. Purification and characterization of a subtilisin D5, a fibrinolytic enzyme of Bacillus amyloliquefaciens DJ-5 isolated from doenjang
AU2003203028A1 (en) Aggrecanase-1 and -2 peptide substrates and methods
SI1539815T1 (sl) Kristalna struktura encima, ki pretvarja angiotenzin (ACE), in njegove uporabe

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application